Introduction
============

The most commonly used method of drug delivery in asthma is inhalation. The advantages of inhaled therapy have been established; it facilitates improved drug delivery to the site of action in minimal doses.^[@bib1]^ However, a high incidence of incorrect use remains a challenge, with 50--90% of patients using their inhalers incorrectly.^[@bib2; @bib3; @bib4; @bib5; @bib6; @bib7; @bib8; @bib9; @bib10]^ This is of critical importance as the inhaler technique has been shown to be associated with asthma control, lung function, perceived control of asthma and quality of life.^[@bib8],[@bib11],[@bib12]^

Fortunately, with appropriate training, patients are able to achieve the correct inhaler technique. However, maintaining the correct inhaler technique over time remains problematic.^[@bib7],[@bib8]^ Approximately 50% of patients have subsequent difficulty in maintaining the correct inhaler technique, irrespective of the inhaler device used or the duration of follow-up (ranging from 2 to 6 weeks after education).^[@bib7],[@bib10],[@bib13; @bib14; @bib15]^

Although there is substantial data on the failure of patients to maintain the correct technique, there is little research on the actual factors that have an impact on inhaler technique maintenance. Recent research has found that maintaining the correct inhaler technique is a complex process and is related to asthma control, inhaler device and motivation.^[@bib16]^ Understanding the way these factors influence correct inhaler technique maintenance is important, and identifying ways in which health-care professionals (HCPs) in practice can deliver more effective inhaler technique education needs to be identified. Understanding the nature and content of the education delivered by HCPs may be the key.

Delivery of inhaler technique education involves two main processes: evaluation of the inhaler technique; and provision of feedback on erroneous steps. Specifically, this involves HCPs observing how the patient uses their inhaler and comparing this technique with an inhaler technique checklist. Depending on the ability of the patient to use the inhaler correctly, the HCP provides specific feedback on how to rectify the errors. It has been found that the nature of this feedback has significant impact on its effectiveness.^[@bib7],[@bib10]^ This suggests that, when reviewing the inhaler technique education delivered to patients, it is important to review the concept of 'feedback'.^[@bib7],[@bib8],[@bib13],[@bib17],[@bib18]^

Feedback can be given qualitatively or quantitatively. Research shows that, when it comes to the optimal delivery of feedback, quantitative feedback should be used.^[@bib19]^ Currently, the nature of feedback in evidence-based inhaler technique educational interventions is qualitative. The aim of this research is to compare the effectiveness of the current best practice, qualitative visual feedback, with a combination of qualitative and quantitative visual feedback on inhaler technique maintenance over time.

Materials and Methods
=====================

Overall study design
--------------------

This study took the form of a cluster-randomised two-arm parallel group, repeated-measures design in which people with asthma received education regarding their inhaler technique in the form of either qualitative visual feedback (verbal feedback with a physical demonstration) (Group 1) or a combination of qualitative and quantitative visual feedback (verbal feedback with physical demonstration plus objective (graphical) feedback) (Group 2). Inhaler technique education was provided by trained community pharmacists who followed up participants after 1 month.

The study was approved by the University of Sydney Ethics Committee. Written informed consent was obtained prior to participation.

Pharmacist training
-------------------

A convenient sample of 19 community pharmacists were recruited and randomised to deliver qualitative visual feedback (Group 1) or a combination of qualitative and quantitative visual feedback (Group 2).

Training of community pharmacists occurred on an individual basis with the researcher (MTS) delivering a 2-h one-on-one training session to each pharmacist in their own community pharmacy.

Group 1 pharmacists were trained as per a train-the-trainer approach and an established pharmacist-training program.^[@bib15]^ A DVD showing HCPs delivering inhaler technique education to people with asthma was used to consolidate the training of pharmacists. Pharmacists also received an update on basic asthma management and inhaled medications.

Group 2 pharmacists were also trained as per a train-the-trainer approach and an established pharmacist-training programme^[@bib15]^ with an additional quantitative feedback process.

The quantitative feedback involved the use of a portable hand-held spirometer (Inhalation Manager (IM, TEVA Pharmaceutical Industries Ltd, Tel Aviv, Israel)), which has been developed with the ability to assess breathing manoeuvres associated with the use of different inhaler devices ([Figure 1](#fig1){ref-type="fig"}). The IM is a preprogrammed device that can measure breathing manoeuvres and provides feedback both in numeric and visual/graphic forms. Actual breathing manoeuvres are then compared with optimal manoeuvres for a particular inhaler. This allows the patient to see exactly where they are making errors and to what extent ([Figure 2](#fig2){ref-type="fig"}). A DVD showing HCPs delivering inhaler technique education to people with asthma was used to consolidate the training of pharmacists (The DVD was funded through Australian Research Council Linkage Project LP LP0882737).^[@bib20]^ Pharmacists also received an update on basic asthma management and inhaled medications.

Participant recruitment
-----------------------

The trained pharmacists identified potential participants as they entered the pharmacy and requested asthma medication or asthma-related advice. Inclusion criteria for participants were as follows: having a diagnosis of asthma and aged ⩾18 years; currently using a Turbuhaler (TH) or Accuhaler (ACC) for the delivery of preventer asthma medication; and having been on the same asthma medication and dose regimen for a minimum of 1 month. Exclusion criteria for participants were as follows: medication not being self-administered; inability to speak or understand English; inability to return for the follow-up visit; and/or being involved in another clinical trial/study.

The purpose of the study was not withheld from the patient participants.

Study visits
------------

Participants were required to visit their pharmacy at the commencement of the study (V1) and after 1 month for a follow-up (V2). At V1, participant data related to demographics, asthma history, asthma medications and previous inhaler technique instructions were collected. Asthma Control was also evaluated (Asthma Control Questionnaire ).^[@bib21]^ The Asthma Control Questionnaire is a validated instrument evaluating asthma control based on symptoms and bronchodilator use. A lower score indicates better asthma control. A score ⩾1.50 means that a patients has an 88% chance of having asthma symptoms that are not well controlled. A change in the Asthma Control Questionnaire score of 0.5 is considered clinically meaningful.^[@bib22]^

The participants' inhaler technique was assessed; they then received inhaler technique feedback based on whether they were randomised to Group 1 or Group 2. Group 1 participants received qualitative visual feedback (verbal feedback with a physical demonstration). Group 2 participants received additional quantitative visual feedback (verbal feedback with physical demonstration plus objective (graphical) feedback) (as described above).

The inhaler technique was reassessed, and Group 1 or Group 2 feedback was repeated until the participant was able to demonstrate the correct technique or after feedback had been provided a maximum of three times.

Participants returned to the pharmacy for a follow-up visit (V2) 4 weeks ±7 days after V1. At this visit, asthma control was evaluated (Asthma Control Questionnaire),^[@bib21]^ and the inhaler technique was reassessed.

### Inhaler technique assessment

The inhaler technique was assessed according to manufacturer-approved checklists ([Table 1](#tbl1){ref-type="table"}). These checklists were developed in collaboration with the National Prescribing Service, Sydney, Australia, through funding from the Australian Research Council Linkage Project LP LP0882737. Individuals were considered to have the correct technique if they were able to perform all steps in the checklist correctly.

Data management
---------------

Demographic data, asthma history, asthma medications and previous asthma technique instructions were analysed descriptively. Asthma control was compared within groups (at V1 and V2) as well as between Group 1 and Group 2. Inhaler technique data were represented in two ways: proportion of participants with correct technique and as the mean number of steps performed correctly for each device.

The proportion of patients with correct technique was determined by the number of participants with the correct technique (able to perform all steps correctly for the respective device) as a percentage of the total number of participants in that group.

Inhaler technique score was determined as the number of steps performed correctly out of the total number of steps for each inhaler.^[@bib23]^ This was standardised between inhalers. For example, the total number of steps required to use an ACC was 10 ([Table 1](#tbl1){ref-type="table"}); if a participant completed only 4 steps correctly, their inhaler technique score was 4. For the TH, the number of steps required to use the inhaler correctly was 11; hence, the TH scores were transformed by a factor of 10/11 for comparison. That is, the total number of steps performed correctly for the TH was divided by '11' and multiplied by '10'.

### Sample size calculation

Based on a study by Basheti *et al*.^[@bib15]^ and an estimated difference of 30% in the proportion of participants with the correct inhaler technique at follow-up (Power=0.8, *P*=0.05), a sample size of 45 participants in each group was required.

On the basis of previous research conducted in a community pharmacy in Australia, involving a cluster design, asthma management and inhaler technique, consistently an intraclass correlation of 0.00 was determined, based on a cluster of 10 participants per pharmacy. This indicated that there is no cluster effect and therefore no need to include a cluster effect in the sample size calculation.^[@bib8],[@bib24; @bib25; @bib26]^

Statistical analysis
--------------------

### Within-group comparisons

Mean inhaler technique scores, mean Asthma Control Scores for V1 and V2 (Wilcoxon's Signed Rank test) and the proportion of patients with correct technique for V1 and V2 (Pearson's Chi-Square test) were compared over time within groups.

### Between-group comparisons

The mean inhaler technique score, the mean Asthma Control Scores (Mann--Whitney *U* test) and the proportion of patients with the correct technique (Pearson's Chi-Square test) were compared between groups. Group comparisons were based on measurements at V1 and V2.

Data were analysed using the IBM Statistical Package for Social Science (SPSS, version 19, IBM, Armonk, NY, USA). A significance level of 0.05 was used.

Results
=======

Of the 101 recruited participants, 97 participants completed the study.

Demographic data of participants are displayed in [Table 2](#tbl2){ref-type="table"}. There were no statistically significant differences between groups with regard to demographic factors (*P*\>0.05, *n*=101, Pearson's Chi-Square test).

Baseline
--------

### Asthma control

There was no statistically significant difference between Group 1 and Group 2 with regard to mean asthma control score at V1 ([Table 2](#tbl2){ref-type="table"}) (1.6 (s.d. 1.0) and 1.7 (s.d. 1.0) respectively *n*=101, *P*=0.4, Mann--Whitney *U* Test).

### Technique

Initially, 4% of Group 1 and 6% of Group 2 demonstrated correct technique (mean inhaler technique scores 6.8 (s.d. 1) and 6.8 (s.d. 1), respectively (mean (s.d.)). There was no statistically significant difference between Group 1 and Group 2 at V1 (proportions: *n*=101, *P*=0.982, Pearson's Chi-Square test; means: *n*=101, *P*=0.975, Mann--Whitney *U* Test).

For the ACC, the most common errors were associated with step 3 (Exhale to residual volume), step 4 (Exhale away from the mouth piece) and step 8 (Hold breath for 5 s).

For the TH, the most common errors were associated with step 2 (Keep inhaler upright during loading), step 4 (Exhale to residual volume) and step 5 (Exhale away from the mouth piece).

At the completion of V1 (training session), all participants in Groups 1 and 2 were able to demonstrate correct technique.

Follow-up
---------

### Effect of education

Compared with V1, at V2 there was a statistically significant increase in the proportion of participants with correct inhaler technique: from 4% to 51% among Group 1 participants and from 6% to 83% among Group 2 participants (Pearson's Chi-Squared, *P*=0.03, *n*=49 and Pearson's Chi-Squared, *P*=0.01, *n*=48, respectively).

The magnitude of increase in the proportion of participants with correct inhaler technique was statistically significantly higher for Group 2 compared with Group 1 (*n*=97, *P*=0.02, Pearson's Chi-Square test) ([Figure 3](#fig3){ref-type="fig"}).

At V2, there was a statistically significant improvement in the mean inhaler technique score from 6.8 (s.d. 1) to 8.9 (s.d. 1) (mean (s.d.)) for Group 1 (Wilcoxon's Signed Rank test, *P*=0.04, *n*= 49) and from 6.8 (s.d. 1) to 9.5 (s.d. 1) (mean (s.d.)) for Group 2 (Wilcoxon's Signed Rank test, *P*=0.02, *n*=48). The magnitude of improvement in Group 2 was statistically significantly greater than that in Group 1 (Mann--Whitney *U* test, *P*=0.002, *n*=97).

For the ACC and TH, the most common errors remained the same, but the proportion of patient participants performing them incorrectly decreased.

At V2, there was no statistically significant difference in mean Asthma Control score for Groups 1 and 2 (1.4 (s.d. 0.8) and 1.3 (s.d. 1.0) respectively, Mann--Whitney *U* Test, *P*=0.5, *n*=97).

There was a statistically significant improvement in the Asthma Control Score in Group 1 when comparing the score at V1 with the score at V2 (1.6 (s.d. 1.0) and 1.4 (s.d. 0.8), respectively, Wilcoxon-Signed Rank test, *P*=0.004, *n*=49).

There was a statistically significant improvement in the Asthma Control Score in Group 2 when comparing score at V1 with the score at V2 (1.7 (s.d. 1.0) and 1.3 (s.d. 1.0), respectively, Wilcoxon's Signed Rank test, *P*=0.03, *n*=48).

Discussion
==========

Main findings
-------------

This study compared the effectiveness of two community pharmacy-delivered educational interventions, one based on qualitative visual feedback^[@bib15]^ and another with additional quantitative visual feedback, on the maintenance of correct inhaler technique over time. These results show that qualitative and quantitative feedback is more effective than qualitative feedback alone. With this dual-format feedback, 83% of participants are able to maintain the correct technique after 1 month. This is significantly higher than that achieved by other research or interventions.^[@bib2; @bib3; @bib4; @bib5; @bib6; @bib7; @bib8; @bib9]^

This study is unique as for the first time it explored the relationship between 'feedback' and inhaler technique. To date, only qualitative feedback has been used in this field of research despite evidence indicating that, when teaching a skill, quantitative feedback is preferred.^[@bib19]^ Therefore, it is not surprising that the quantitative feedback evaluated in this research was more effective in maintaining the skill of correct inhaler technique over time when compared with the more traditional qualitative feedback. Quantitative feedback (through the graphical representation of inhaler technique, which is compared with optimal technique by the IM) provides a tangible quantitative goal for the patient, allowing them to conceptualise exactly what errors they need to correct (e.g., if they are not breathing in 'forcefully and deeply' how much is enough?). Objective (graphical) feedback (as tested in this research) is a form of visual feedback that may be a way to help 'quantify' the information provided.^[@bib27],[@bib28]^ Further, an important component of learning a skill and improving performance is the ability to detect and correct errors.^[@bib29]^ The quantitative feedback used in this research is therefore also helpful in goal setting, which the patient can quantify to a tangible and attainable extent. The feedback from the IM allows a pharmacist to articulate this goal more clearly. The steps associated with breathing manoeuvres are also quite subjective to 'reflect on', and therefore there is an opportunity for miscommunication with regard to what extent the breathing manoeuvres described should be carried out. In other words, unless patients can objectively identify a goal, they may only subjectively evaluate their technique. This is primarily because, up until now, HCPs have had no quantitative means of providing feedback with regard to inhaler technique.

Interpretations of findings in relation to previously published work
--------------------------------------------------------------------

The new method of education explored in this study incorporated the theoretical framework associated with the concept of 'feedback' and, in so doing, proved to be more effective than the current evidence-based inhaler technique education delivered through the community pharmacy. One month after the interventions were delivered, 51% of patient participants in the standard intervention group (Group 1) continued to have an incorrect inhaler technique. This is consistent with previously published studies that have found that approximately 50% of patients who receive education via a physical demonstration by the HCP using a placebo inhaler continue to have an incorrect technique 1 month after their training session.^[@bib7]^ In this research, the participants who received verbal feedback, physical demonstration and the quantitative visual feedback were significantly more likely to maintain the correct inhaler technique, with 83% of participants being able to maintain the correct technique. This is a vast improvement in the maintenance of correct technique from that previously demonstrated in other research.^[@bib2; @bib3; @bib4; @bib5; @bib6; @bib7; @bib8; @bib9]^

When it comes to the actual steps performed incorrectly, for the TH, holding the device upright, exhaling to residual volume prior to inhalation and exhaling away from the inhaler were the most problematic steps; for the ACC, exhaling to residual volume, exhaling away from the inhaler and holding breath for 5 s were most commonly performed incorrectly. These results are consistent with the findings of many previous studies.^[@bib5],[@bib6],[@bib15],[@bib30; @bib31; @bib32]^ With regard to the quantitative feedback provided by the IM, it is important to note that the specific steps for which the quantitative feedback is provided are not necessarily those for which the IM provides feedback. Despite this, the quantitative feedback was more effective than the qualitative feedback (verbal plus physical demonstration) alone. There may be several explanations for this. One of them may relate to participant confidence; i.e., by providing the participants with visual quantitative feedback, they may have been reassured about their ability to use the inhalers. It is also possible that once they were reassured of the steps they performed correctly (e.g., breathing in forcefully and deeply) they were more likely to concentrate on the problematic incorrect steps that they had been shown. The use of quantitative feedback may also have had a role in motivating patients to use their device correctly. Ovchinikova *et al.* ^[@bib16]^ found that patient motivation was a determining factor in device technique maintenance.

Implications for future research, policy and practice
-----------------------------------------------------

This research highlights the importance of feedback in educating patients in the correct use of their Dry Powder Inhalers. Future research should aim to explore this novel educational intervention in the maintenance of inhaler technique in those patients using other devices -- e.g., the pressurised metered dose inhaler. Both groups showed significant improvement in asthma control at the 1-month follow-up. Although a link between inhaler technique and asthma control has previously been shown,^[@bib8]^ asthma control can be attributed to factors other than inhaler technique. These may be related to adherence, trigger avoidance, improved self-management, smoking cessation, etc, during the study. Thus, further exploration of the nature of the relationship between inhaler technique and asthma control is needed.

Strengths and limitations of this study
---------------------------------------

The major strength of this study lies in the fact that this study explored a new approach to feedback and has shown that this makes a difference in inhaler technique maintenance. The main limitation lies in the impact of the IM on the pharmacist's ability to evaluate the technique. Potentially, pharmacists utilising the IM to deliver education may have had more interaction both with the researcher and with the patient participant. This may have positively influenced their ability to evaluate the technique.

Conclusions
-----------

This study shows that an educational intervention for inhaler technique, which is based on both qualitative and quantitative feedback, is more effective than one based on qualitative feedback alone in maintaining the correct inhaler technique over time. Further studies are needed to explore whether this effect is maintained beyond the study follow-up period and the nature of the relationship between asthma control and inhaler technique.
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###### Itemised list of steps required to administer medication via an Accuhaler and Turbuhaler

  *Step*   *Turbuhaler (TH)*                                             *Accuhaler (ACC)*
  -------- ------------------------------------------------------------- -------------------------------------------------------------------------------------
  1        Unscrew and remove the cap from the inhaler                   Open lever
  2        Keep inhaler upright                                          Push lever back completely to load dose
  3        Rotate grip one way, then back, to load dose                  Exhale all air out of lungs
  4        Exhale all air out of lungs                                   Exhale away from the mouthpiece[a](#t1-fn1){ref-type="fn"}
  5        Exhale away from the mouthpiece[a](#t1-fn1){ref-type="fn"}    Hold Inhaler horizontally
  6        Keep head upright, lift chin slightly                         Place mouthpiece between teeth and seal with lips
  7        Place mouthpiece between teeth and seal with lips             Inhale slowly and deeply[a](#t1-fn1){ref-type="fn"}
  8        Inhale forcefully and deeply[a](#t1-fn1){ref-type="fn"}       Hold breath for as long as is comfortable (aim for 10 s)[a](#t1-fn1){ref-type="fn"}
  9        Pause, then breathe out normally[a](#t1-fn1){ref-type="fn"}   Exhale away from the inhaler[a](#t1-fn1){ref-type="fn"}
  10       Exhale away from the inhaler                                  Close inhaler
  11       Replace cap                                                   

Based on checklists developed in collaboration with the National Prescribing Service (Sydney, Australia) and manufacturer approved.

Steps for which the Inhalation Manager provided additional visual feedback.

###### Participant characteristics

                                                                      *All participants (*n=*101)*   *Group 1 (*n=*50)*   *Group 2 (*n=*51)*
  ------------------------------------------------------------------ ------------------------------ -------------------- --------------------
  Female, *n* (%)                                                              66 (65.3%)                 35 (70%)            31 (60.8%)
  Accuhaler users, *n* (%)                                                     54 (53.5%)                 26 (52%)            28 (54.9%)
                                                                                                                                   
  *Age*                                                                                                                  
   18--25 years                                                                24 (23.8%)                11 (22.0%)           13 (25.5%)
   26--40 years                                                                21 (20.8%)                11 (22.0%)           10 (19.6%)
   41--60 years                                                                25 (24.8%)                10 (20.0%)           15 (29.4%)
   61+years                                                                    31 (30.7%)                18 (36.0%)           13 (25.5%)
                                                                                                                         
  Previous information received on how to use the inhaler, *n* (%)             89 (88.0%)                41 (82.0%)           48 (94.0%)
                                                                                                                                   
  *Source of previous inhaler information,* n *(%)*                                                                      
   General practitioner                                                        48 (54.5%)                24 (58.5%)           24 (50.0%)
   Pharmacist                                                                  15 (16.9%)                6 (14.6%)            9 (18.8%)
   A doctor+a pharmacist                                                       23 (25.8%)                10 (24.3%)           13 (27.1%)
   CMI                                                                          2 (2.2%)                  1 (2.4%)             1 (2.1%)
   Pulmonary nurse                                                              1 (1.1%)                   0 (0%)              1 (2.1%)
                                                                                                                                   
  *Form of information previously received,* n *(%)*                                                                     
   PD+VI                                                                       35 (39.3%)                18 (43.9%)           17 (35.4%)
   VI only                                                                     19 (21.3%)                10 (24.4%)           9 (18.75%)
   WI only                                                                     13 (14.6%)                5 (12.2%)            8 (16.7%)
   WI+VI                                                                        1 (1.1%)                  1 (2.4%)              0 (0%)
   WI+PD+VI                                                                    21 (23.6%)                7 (17.1%)            14 (29.2%)
                                                                                                                                   
  *Time length since last duration,* n *(%)*                                                                             
   \<1 month                                                                    2 (2.2%)                  2 (4.9%)              0 (0%)
   1--5 months                                                                 19 (21.3%)                8 (19.5%)            11 (22.9%)
   6--11 months                                                                 7 (7.9%)                  2 (4.9%)            5 (10.4%)
   1--2 years                                                                  26 (29.2%)                13 (31.7%)           13 (27.1%)
   \>2 years                                                                   35 (39.3%)                16 (39.0%)           19 (39.6%)
                                                                                                                         
  Asthma Control Questionnaire score at baseline (mean±s.d.)                   1.67±0.98                 1.70±1.01            1.60±0.96

Abbreviations: CMI, consumer medicine information; IM, Inhalation Manager; PD, physical demonstration; VI, verbal information; WI, written information; WI, written information. *n*=49 in Group 1 (ACC, *n*=27; TH, *n*=22), *n*=48 in Group 2 (ACC, *n*=26; TH, *n*=22).
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